quetiapine
A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.
Ligand Summary
UNII: BGL0JSY5SI
PubChem: 5281025
PubChem: 5002
Guide to Pharmacology: 50
ChEMBL: CHEMBL3188993
ChEMBL: CHEMBL716
DrugCentral: 2337
LyCHI: KT7VY43USC7W
Target Activities
HTR2A
5-hydroxytryptamine receptor 2A
7 Activities
Items per page:
1 – 7 of 7
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
7 | ||||||
Ki | 7.51 | Bioorg Med Chem Lett, (2019) 29:21:126679 | ||||
Ki | 7.47 | None, None:None:None | ||||
Ki | 7.2 | J. Med. Chem., (2007) 50:21:5103 | ||||
Ki | 7.09 | J. Med. Chem., (2001) 44:4:477 | ||||
Ki | 7 | J. Med. Chem., (2012) 55:4:1572 | ||||
IC50 | 7.13 | ANTAGONIST | ||||
HRH1
Histamine H1 receptor
6 Activities
Items per page:
1 – 6 of 6
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 8.34 | None, None:None:None | ||||
Ki | 8.06 | Bioorg. Med. Chem., (2008) 16:15:7291 | ||||
Ki | 8 | MedChemComm, (2012) 3:5:580 | ||||
Ki | 7.72 | J. Med. Chem., (2004) 47:6:1303 | ||||
Ki | 7.68 | J. Med. Chem., (2001) 44:4:477 | ||||
IC50 | 7.4 | None, None:None:None | ||||
DRD2
D(2) dopamine receptor
4 Activities
Items per page:
1 – 4 of 4
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.2 | |||||
Ki | 7.2 | Bioorg. Med. Chem. Lett., (2001) 11:10:1313 | ||||
Ki | 7.16 | J. Med. Chem., (2001) 44:4:477 | ||||
IC50 | 6.48 | ANTAGONIST | ||||
ADRA1A
Alpha-1A adrenergic receptor
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.7 | None, (2013) None:None:None | ||||
Ki | 7 | MedChemComm, (2012) 3:5:580 | ||||
CHRM1
Muscarinic acetylcholine receptor M1
2 Activities
ADRA1D
Alpha-1D adrenergic receptor
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.32 | None, None:None:None | ||||
IC50 | 7.01 | None, None:None:None | ||||
ADRA2B
Alpha-2B adrenergic receptor
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.34 | None, None:None:None | ||||
IC50 | 7 | None, None:None:None | ||||
KCNH2
Potassium voltage-gated channel subfamily H member 2
2 Activities
ADRA2C
Alpha-2C adrenergic receptor
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.21 | None, None:None:None | ||||
Ki | 7 | MedChemComm, (2012) 3:5:580 | ||||
H1F0
Histone H1.0
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 8 | None, (2013) None:None:None | ||||
Ki | 8 | |||||
HTR1D
5-hydroxytryptamine receptor 1D
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
5.7 | ||||||
HTR1E
5-hydroxytryptamine receptor 1E
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
5.9 | ||||||
HTR1F
5-hydroxytryptamine receptor 1F
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
5.6 | ||||||
SLC6A2
Sodium-dependent noradrenaline transporter
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 6.03 | |||||
SIGMAR1
Sigma non-opioid intracellular receptor 1
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 6.02 | None, None:None:None | ||||
ADRA1B
Alpha-1B adrenergic receptor
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7 | MedChemComm, (2012) 3:5:580 | ||||
HTR1A
5-hydroxytryptamine receptor 1A
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.1 | J. Med. Chem., (2007) 50:21:5103 | ||||
HTR7
5-hydroxytryptamine receptor 7
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.2 | J. Med. Chem., (2007) 50:21:5103 | ||||